Success Metrics

Clinical Success Rate
76.5%

Based on 13 completed trials

Completion Rate
76%(13/17)
Active Trials
0(0%)
Results Posted
85%(11 trials)
Terminated
4(22%)

Phase Distribution

Ph phase_4
4
22%
Ph phase_2
9
50%
Ph phase_3
4
22%
Ph phase_1
1
6%

Phase Distribution

1

Early Stage

9

Mid Stage

8

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
1(5.6%)
Phase 2Efficacy & side effects
9(50.0%)
Phase 3Large-scale testing
4(22.2%)
Phase 4Post-market surveillance
4(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.5%

13 of 17 finished

Non-Completion Rate

23.5%

4 ended early

Currently Active

0

trials recruiting

Total Trials

18

all time

Status Distribution
Completed(13)
Terminated(4)
Other(1)

Detailed Status

Completed13
Terminated4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
0
Success Rate
76.5%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (5.6%)
Phase 29 (50.0%)
Phase 34 (22.2%)
Phase 44 (22.2%)

Trials by Status

terminated422%
completed1372%
unknown16%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT03735979Phase 3

Multi-arm Optimization of Stroke Thrombolysis

Completed
NCT01522417Phase 2

Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

Completed
NCT02925923Phase 2

Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel

Completed
NCT01919723Phase 2

Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion

Completed
NCT01076764Phase 3

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

Completed
NCT01977456Phase 2

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)

Completed
NCT00317395Phase 2

Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome

Completed
NCT00894803Phase 2

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

Completed
NCT00111566Phase 4

BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention

Completed
NCT01863134Phase 4

Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up

Completed
NCT00834899Phase 1

A Safety Study of Eptifibatide in Patients With Sickle Cell Disease

Terminated
NCT00061373Phase 2

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

Completed
NCT00426751Phase 3

Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)

Completed
NCT00719914Phase 2

A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks

Terminated
NCT01454440Phase 4

The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT)

Terminated
NCT00638976Phase 3

INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial

Completed
NCT00945308Phase 2

Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients

Unknown
NCT00289601Phase 4

Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty

Terminated

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18